This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?

The STORM report: implications for care

The appropriate use of sibutramine in Primary care is discussed by Dr Ian Campbell, Chair of the National Obesity Forum

Campbell Park House Medical Centre, 61 Burton Rd, Carlton, Nottingham, NG4 3DQ, UK, iwc9{at}yahoo.com

Sibutramine is a newly available satiety-inducing agent which also increases energy expenditure. Its efficacy was evaluated with a two-year controlled study called STORM (Sibutramine Trial of Obesity Reduction and Maintenance). 605 obese subjects (BMI 30—45 kg/m²) were recruited, and 499 completed an initial six months of exercise, diet and sibutramine (10 mg/day) therapy. 93% achieved >5% weight loss. After a further 18 months of this treatment most subjects maintained 80% of their body weight loss whereas subjects receiving placebo tablets regained over 75% of their weight loss. The STORM trial suggests that sibutramine promotes weight loss and may assist weight control in obese subjects unable to maintain adequate dietary regimens, whereas efficacy of the pancreatic lipase inhibitor orlistat is dependent on dietary compliance.

Key Words: sibutramine • serotonin noradrenaline re-uptake inhibitor • obesity • STORM study.

The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 2, 118-121 (2001)
DOI: 10.1177/14746514010010021001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?